Beam Therapeutics Overview
- Founded
- 2017

- Status
- Public
- Employees
- 341

- Stock Symbol
- BEAM

- Investments
- 2
- Share Price
- $34.99
- (As of Monday Closing)
Beam Therapeutics General Information
Description
Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing.
Contact Information
- 26 Landsdowne Street
- 2nd Floor
- Cambridge, MA 02139
- United States
Beam Therapeutics Timeline
Beam Therapeutics Stock Performance
(As of Monday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$34.99 | $35.19 | $27.77 - $138.52 | $2.46B | 70.3M | 1.19M | -$3.61 |
Beam Therapeutics Financials Summary
In Thousands, USD |
TTM 31-Mar-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
---|---|---|---|---|
EV | 3,120,245 | 4,641,777 | 4,564,455 | |
Revenue | 60,270 | 51,844 | 24 | 18 |
EBITDA | (229,582) | (363,178) | (190,908) | (77,051) |
Net Income | (238,292) | (370,638) | (194,592) | (78,326) |
Total Assets | 1,453,402 | 1,474,453 | 451,677 | 156,099 |
Total Debt | 150,134 | 147,644 | 107,644 | 31,238 |
Beam Therapeutics Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
This information is available in the PitchBook Platform. To explore Beam Therapeutics‘s full profile, request access.
Request a free trialBeam Therapeutics Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
---|
This information is available in the PitchBook Platform. To explore Beam Therapeutics‘s full profile, request access.
Request a free trialBeam Therapeutics Comparisons
Industry
0000000
0000000
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trialBeam Therapeutics Competitors (56)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
EdiGene | Venture Capital-Backed | Beijing, China | 000 | 00000 | 00000000000 | 00000 |
0000000 0000000000 | Formerly VC-backed | Brisbane, CA | 000 | 0000 | 00000000 | 0000 |
000000000 00000000 | Venture Capital-Backed | Hayward, CA | 00 | 000.00 | 00000000000 | 000.00 |
0000000 0000000000 | Formerly VC-backed | Berkeley, CA | 00 | 00000 | 00000000 | 00000 |
00000 000000000000 | Venture Capital-Backed | Cambridge, MA | 00 | 00000 | 00000000000 | 00000 |
Beam Therapeutics Patents
Beam Therapeutics Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
AU-2020279751-A1 | Methods of editing a single nucleotide polymorphism using programmable base editor systems | Pending | 21-May-2019 | 0000000000 | |
CA-3139324-A1 | Compositions and methods for treating hepatitis b | Pending | 10-May-2019 | 0000000000 | |
AU-2020276218-A1 | Compositions and methods for treating hepatitis b | Pending | 10-May-2019 | 0000000000 | |
AU-2020223306-A1 | Methods of editing a disease-associated gene using adenosine deaminase base editors, including for the treatment of genetic disease | Pending | 13-Feb-2019 | 000000000 | |
CA-3128876-A1 | Methods of editing a disease-associated gene using adenosine deaminase base editors, including for the treatment of genetic disease | Pending | 13-Feb-2019 | A61K48/00 |
Beam Therapeutics Executive Team (14)
Beam Therapeutics Board Members (9)
Name | Representing | Role | Since |
---|---|---|---|
Carole Ho MD | Self | Board Member | 000 0000 |
Graham Cooper | Self | Board Member | 000 0000 |
John Evans | Beam Therapeutics | Chief Executive Officer & Board Member | 000 0000 |
John Maraganore Ph.D | Self | Board Member | 000 0000 |
Kathleen Walsh | Self | Board Member | 000 0000 |
Beam Therapeutics Signals
Growth Rate

Growth

Size Multiple


Key Data Points
Twitter Followers
5.5k

Similarweb Unique Visitors
15.0K

Majestic Referring Domains
314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialBeam Therapeutics Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
This information is available in the PitchBook Platform. To explore Beam Therapeutics‘s full profile, request access.
Request a free trialBeam Therapeutics Acquisitions (2)
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
00000 0000000 | 23-Feb-2021 | 0000000000 | 00000 | Drug Delivery | 0000 0000 |
BliNK Therapeutics | 01-Sep-2018 | Merger/Acquisition | Biotechnology |